Clinical trials
Leukemia Acute Myeloid - AML clinical trials
Below are recruiting leukemia acute myeloid - aml clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06764238RecruitingPhase 2/Phase 3
Treatment study for children with new B-cell ALL (intermediate/high risk)
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT06599762RecruitingPhase 2
Tranexamic acid for bleeding in MDS and AML
This trial tests if tranexamic acid, a medicine that helps blood clot, can reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have very low platelet counts and are receiving less-intensive chemotherapy.
Winnipeg, ManitobaAges 18 years+ - NCT06551584RecruitingPhase 1
Advanced blood cancer trial with stem cell transplant
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
Palo Alto, CaliforniaAges 18–70 - NCT06535113Recruiting
Inflammation and treatment response in AML
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
Reggio Calabria, CalabriaAges 18 years+ - NCT06466395RecruitingPhase 1
Hyper-CVAD plus venetoclax for relapsed pediatric leukemia
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
Houston, TexasAges 2–21 - NCT06297551Recruiting
Study of leukemia stem cell markers in AML
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
Stony Brook, New YorkAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT04260022RecruitingPhase 1
Drug study for hard-to-treat CML or Ph+ ALL
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Birmingham, AlabamaAges 18 years+ - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT05792007Recruiting
Study of bone marrow environment in childhood leukemia
This study looks at what the bone marrow “microenvironment” is like in children newly diagnosed with acute leukemia, to better understand the disease. It also compares leukemia samples to samples from children having certain orthopedic surgery.
ToursAges 1–15 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05807932RecruitingPhase 1/Phase 2
Venetoclax added to conditioning before stem cell transplant
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
Aachen, North Rhine-WestphaliaAges 18 years+ - NCT05322850RecruitingPhase 1/Phase 2
Engineered donor stem cell transplant for childhood blood cancers
This trial tests a new way to prepare donor stem cells before a transplant for children and young adults with blood cancers. The goal is to make the transplant safer and more effective, potentially reducing complications like graft-versus-host disease.
Gainesville, FloridaAges Up to 50 years - NCT05304377RecruitingPhase 1
Early trial drug for chronic-phase CML after prior treatments
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
New York, New YorkAges 18 years+ - NCT04925479RecruitingPhase 1/Phase 2
Testing asciminib dosing and safety for teen CML patients
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
Indianapolis, IndianaAges 1–17 - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Duarte, CaliforniaAges 12–78 - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT03633955RecruitingPhase 1
Imaging study for people with high-risk leukemia
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
Washington D.C., District of ColumbiaAges 4–80 - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
Hartford, ConnecticutAges 18–80 - NCT07499765Recruiting
Support program for newly diagnosed acute leukemia patients
This study tests whether a formal support program can help people newly diagnosed with acute leukemia. If you're starting treatment at the Centre Henri Becquerel, this program may offer extra guidance and help improve your quality of life.
RouenAges 26–80 - NCT06368414RecruitingPhase 2
Stopping TKI in CML after asciminib
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Incheon, IncheonAges 19 years+
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia acute myeloid - aml?
- Yes. Clin2 currently lists 90 recruiting leukemia acute myeloid - aml studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia acute myeloid - aml trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia acute myeloid - aml trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.